← Back to Search

Antibiotic

Vancomycin for Clostridium Difficile Infection

Phase 4
Waitlist Available
Led By Andrew Maternowski, MD
Research Sponsored by Spectrum Health Hospitals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

We are doing this research study to determine if taking vancomycin in addition to a broad-spectrum antibiotic will decrease the chance of developing recurrent Clostridium difficile infection.

Eligible Conditions
  • Clostridium Difficile Infection

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The incidence of recurrent Clostridium difficile infection

Trial Design

1Treatment groups
Experimental Treatment
Group I: VancomycinExperimental Treatment2 Interventions
Vancomycin 125 mg PO QD vs Placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Vancomycin
FDA approved

Find a Location

Who is running the clinical trial?

Spectrum Health HospitalsLead Sponsor
64 Previous Clinical Trials
553,069 Total Patients Enrolled
Andrew Maternowski, MDPrincipal InvestigatorSpectrum Health Hospitals

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~13 spots leftby Apr 2025